Study compares effectiveness of psoriasis treatments

Study compares effectiveness of psoriasis treatments
The effectiveness of therapies for psoriasis is variable, and may be lower in real-world settings than in trial settings, according to a study published in the April issue of the Archives of Dermatology.

(HealthDay) -- The effectiveness of therapies for psoriasis is variable, and may be lower in real-world settings than in trial settings, according to a study published in the April issue of the Archives of Dermatology.

Joel M. Gelfand, M.D., M.S.C.E., of the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues compared the effectiveness of biologic systemic therapy, nonbiologic , and phototherapy for treatment of psoriasis in a cohort of 713 patients with plaque psoriasis. Participants received monotherapy (methotrexate sodium, , , or ustekinumab) or narrowband ultraviolet (UV)-B phototherapy. The primary outcome was clear or almost clear skin on the Physician Global Assessment Scale.

The researchers found that the proportion of patients who achieved the primary outcome was 23.8 percent with methotrexate, 47.7 percent with adalimumab, 34.2 percent with etanercept, 36.1 percent with ustekinumab, and 26.1 percent with narrowband UV-B. Patients receiving adalimumab, etanercept, and ustekinumab were significantly more likely to achieve the primary outcome than those receiving methotrexate, whereas there was no significant difference for those receiving phototherapy versus methotrexate. There was no response difference seen for quality of life.

"The effectiveness of psoriasis therapies in clinical practice may be lower than that reported in previous trials," the authors write. "These results provide novel benchmarks emphasizing the critical importance of studying effectiveness in real-world practice."

Several authors disclosed financial ties to the pharmaceutical and biotechnology industries.

More information: Arch Dermatol. 2012;148(4):487-494. doi:10.1001/archdermatol.2012.370

add to favorites email to friend print save as pdf

Related Stories

Scientists put psoriasis drugs to the test

Jan 13, 2010

Clinical trials to test the effectiveness of two prescription drugs for the debilitating skin condition psoriasis have revealed significant differences that should help inform physicians treating patients with the condition.

UV-B treatment may improve psoriasis and vitamin D levels

Aug 16, 2010

Treatment with narrow-band UV-B rays may increase serum levels of vitamin D in the wintertime while clearing psoriasis, according to a report in the August issue of Archives of Dermatology, one of the JAMA/Archives journa ...

Costs of psoriasis treatments outpace inflation

Jan 18, 2010

Findings from a cost model suggest that expenses for systemic psoriasis therapy appear to be increasing at a faster rate than inflation, and newer biologically derived treatments are more expensive than traditional systemic ...

Recommended for you

US lawmaker: New case raises questions on Ebola

12 minutes ago

The new case of Ebola diagnosed in New York City has raised "even more questions about procedures in treating patients and risks to Americans," a Republican committee chairman said Friday.

Aid group: Ebola contagion risk can't be zero

40 minutes ago

Despite stringent infection-control measures, the risk of Ebola's spread cannot be entirely eliminated, Doctors Without Borders said Friday after one of its doctors caught the dreaded disease while working in Guinea and went ...

WHO eyes mass Ebola vaccines by mid-2015

50 minutes ago

Hundreds of thousands of Ebola vaccine doses could be rolled out to west Africa by the middle of next year, the World Health Organization said Friday, after new cases of the killer virus were reported in New York and Mali.

User comments